FrancophonIA/ELRC3.0 huggingface dataset:
English: Nervous system disorders dizziness, nystagmus, memory impairment, headache, somnolence dysarthria, amnesia, dysgeusia, tremor, balance impaired, ataxia, aphasia, burning sensation, sedation, paraesthesia, hypoaesthesia, disturbance in attenti on, speech disorder, areflexia, coordination abnorm al, dizziness postural, cognitive disorder, hyperaesthesia, hyporeflexia, ageusia, depressed level of consciousness, dysaesthesia, parosmia, mental impairment incoherence, loss of consciousness, coma, stupor, convulsions, cerebrovascular accident, encephalopathy
Latvian: Nervu sistēmas traucējumi reibonis, nistagms, atmiņas traucējumi, galvassāpes, miegainība dizartrija, amnēzija, garšas traucējumi, tremors, līdzsvara traucējumi, ataksija, afāzija, dedzinoša sajūta, nomierināšanās, parestēzijas, hipoestēzija, uzmanības traucējumi, runas traucējumi, arefleksija, koordinācijas traucējumi, posturālais reibonis, kognitīvie traucējumi, hiperestēzija, hiporefleksija, garšas zudums, nomākta apziņa, jutīguma traucējumi, ožas traucējumi, intelektuālās darbības traucējumi nesakarīgums, bezsamaņa, koma, stupors, konvulsijas, cerebrovaskulārie traucējumi, encefalopātija
English: However monitoring of creatine kinase is recommended.
Latvian: Kreatīnkināzes līmeni ieteicams kontrolēt.
English: EU/1/04/302/002 - 2 ml solution for infusion.
Latvian: EU/1/04/302/002 - 2 ml šķīdums infūzijām.
English: Median
Latvian: Metionīns
English: 1 vial of 1 ml 1ml
Latvian: Viens 1 ml flakons 1 ml
English: Gastrointestinal disorders nausea, vomiting diarrhoea, dry mouth, constipation, nausea aggravated, upper abdominal pain dyspepsia
Latvian: Kuņģa-zarnu trakta traucējumi slikta dūša, vemšana caureja, sausums mutē, aizcietējums, slikta dūša, sāpes vēdera augšdaļā dispepsija
English: Each 5 ml vial contains 500 μg ziconotide (as acetate).
Latvian: Katrs 5 ml flakons satur 500 μg zikonotīda (acetāta veidā).
English: Management
Latvian: Kontrole
English: The solution should not be used if discoloured or cloudy or if particulate matter is observed.
Latvian: Šķīdumu nedrīkst lietot, ja šķīduma krāsa izmainījusies, tas kļuvis duļķains vai redzamas daļiņas.
English: General disorders and administration site conditions gait abnormal, asthenia fatigue, pyrexia, lethargy, oedema peripheral, rigors, fall, chest pain, feeling cold, pain, feeling jittery, pain exacerbated difficulty in walking
Latvian: Vispārēji traucējumi un reakcijas ievadīšanas vietā gaitas traucējumi, astēnija nogurums, hipertermija, letarģija, perifērā tūska, drebuļi, ģībonis, sāpes krūtīs, aukstuma sajūta, sāpes, nervozitātes sajūta, pastiprinātas sāpes apgrūtināta staigāšana
English: MARKETING AUTHORISATION NUMBER(S) EU/1/04/302/004 - 20 ml solution for infusion
Latvian: EU/1/04/302/004 - 20 ml šķīdums infūzijām
English: NAME OF THE MEDICINAL PRODUCT Prialt 100 micrograms/ml solution for infusion ziconotide
Latvian: ZĀĻU NOSAUKUMS Prialt 100 mikrogrami/ml šķīdums infūzijām ziconotide
English: NAME OF THE MEDICINAL PRODUCT Prialt 25 micrograms/ml solution for infusion
Latvian: ZĀĻU NOSAUKUMS Prialt 25 mikrogrami/ml šķīdums infūzijām
English: NAME OF THE MEDICINAL PRODUCT Prialt 25 micrograms/ml solution for infusion ziconotide
Latvian: ZĀĻU NOSAUKUMS Prialt 25 mikrogrami/ml šķīdums infūzijām ziconotide
English: Each 20 ml vial contains 500 μg ziconotide (as acetate).
Latvian: Katrs 20 ml flakons satur 500 μg zikonotīda (acetāta veidā).
English: CE marked pumps equivalent to the Synchromed and CADD-Micro pump should be used to deliver Prialt.
Latvian: Prialt ievadīšanai jāizmanto CE iezīmēti sūkņi, kas ir līdzvērtīgi Synchromed un CADD-mikrosūkņiem.
English: NAME OF THE MEDICINAL PRODUCT Prialt 100 micrograms/ml solution for infusion
Latvian: ZĀĻU NOSAUKUMS Prialt 100 mikrogrami/ml šķīdums infūzijām
English: - One ml solution contains 100 micrograms ziconotide (as acetate).
Latvian: - Viens ml šķīduma satur 100 mikrogramus zikonotīda (acetāta veidā).
English: Each vial contains 200 micrograms ziconotide (as acetate).
Latvian: Katrs flakons satur 200 mikrogramus zikonotīda (acetāta veidā).
English: - The other ingredients (excipients) are methionine, sodium chloride, water for injections,
Latvian: - Citas sastāvdaļas (palīgvielas) ir metionīns, nātrija hlorīds, ūdens injekcijām, sālsskābe un nātrija hidroksīds.
English: PHARMACEUTICAL FORM Solution for infusion (infusion).
Latvian: Prialt ir šķīdums infūzijām (infūzijām).
English: Each 1 ml vial contains 100 μg ziconotide (as acetate).
Latvian: Katrs 1 ml flakons satur 100 μg zikonotīda (acetāta veidā).
English: Skin and subcutaneous tissue disorders pruritus, sweating increased rash
Latvian: Ādas un zemādas audu bojājumi nieze, pastiprināta svīšana izsitumi
English: Caution should be exercised when ziconotide is administered to patients with impaired renal function.
Latvian: Ievadot zikonotīdu pacientiem ar aknu darbības traucējumiem, jāievēro piesardzības pasākumi.
English: Dose at end of titration (μg/hr)
Latvian: Vidējais SIVAS rezultāts sākotnējas titrēšanas beigās, mm (SN)
English: Each ml contains 100 micrograms ziconotide (as acetate).
Latvian: Katrs mililitrs satur 100 mikrogramus zikonotīda (acetāta veidā).
English: Each vial contains 100 micrograms ziconotide (as acetate).
Latvian: Katrs flakons satur 100 mikrogramus zikonotīda (acetāta veidā).
English: Prialt should be inspected visually for particulate matter and discolouration prior to administration.
Latvian: Prialt pirms ievadīšanas vizuāli jāpārbauda, vai nav daļiņu un krāsas maiņas.
English: It should be inspected visually for particulate matter and discolouration prior to administration.
Latvian: Pirms ievadīšanas vizuāli jāpārbauda, vai nav daļiņu un krāsas maiņas.
English: Reporting of side effects If you get any side effects, talk to your doctor.
Latvian: Ja Jums rodas jebkādas blakusparādības, konsultējieties ar ārstu.
English: STATEMENT OF ACTIVE SUBSTANCE(S) Each ml contains 25 micrograms ziconotide (as acetate) Each vial contains 500 micrograms ziconotide (as acetate).
Latvian: NOSAUKUMS(-I) UN DAUDZUMS(-I) Katrs mililitrs satur 25 mikrogramus zikonotīda (acetāta veidā)
English: MARKETING AUTHORISATION NUMBER(S) EU/1/04/302/001 - 1 ml solution for infusion.
Latvian: EU/1/04/302/001 - 1 ml šķīdums infūzijām.
English: Mean VASPI score at baseline in mm (SD)
Latvian: Vidējais SIVAS rezultāts sākumpunktā, mm (SN)
English: _ _1 Neisseria meningitidis serogroup A polysaccharide* 5 micrograms Neisseria meningitidis serogroup C polysaccharide* 5 micrograms Neisseria meningitidis serogroup W-135 polysaccharide* 5 micrograms Neisseria meningitidis serogroup Y polysaccharide* 5 micrograms *conjugated to tetanus toxoid carrier protein 44 micrograms
Latvian: 5 mikrogrami W-135 serogrupas Neisseria meningitidis polisaharīds*
English: 1 vial + 1 prefilled syringe
Latvian: 1 flakons + 1 pilnšļirce
English: Ref.: EMEA/619504/2009 EMEA/H/C/1071
Latvian: Atsauces dok.: EMEA/619517/2009 EMEA/H/C/1071
English: It is used after at least one other treatment has failed;
Latvian: Tās lieto pēc tam, kad vismaz viena cita terapija bijusi nesekmīga;
English: This is repeated every 21 days for six courses or until the disease gets worse.
Latvian: Šo ārstēšanas kursu atkārto ik pēc 21 dienas, līdz veikti seši kursi vai arī kamēr slimība atsāk progresēt.
English: Topotecan Teva is given as an infusion lasting 30 minutes every day for five days with a three-week interval between the start of each course.
Latvian: Topotecan Teva ievada ar infūziju, kas ilgst 30 minūtes, katru dienu piecu dienu laikā, ievērojot trīs nedēļu intervālu starp katra ārstēšanas kursa sākumu.
English: This means that Topotecan Teva is similar to a ‘reference medicine' already authorised in the European Union (EU) called Hycamtin.
Latvian: Tas nozīmē, ka Topotecan Teva ir līdzīgas „atsauces zālēm”, kas jau ir reģistrētas Eiropas Savienībā (ES) ar nosaukumu Hycamtin.
English: The European Commission granted a marketing authorisation valid throughout the EU for Topotecan Teva to Teva Pharma B.V. on 21 September 2009.
Latvian: Eiropas Komisija 2009. gada 21. septembrī izsniedza Topotecan Teva reģistrācijas apliecību, kas derīga visā Eiropas Savienībā, uzņēmumam Teva Pharma B.V.
English: The Committee for Medicinal Products for Human Use (CHMP) concluded that, in accordance with EU requirements, Topotecan Teva has been shown to be comparable to Hycamtin.
Latvian: Cilvēkiem paredzēto zāļu komiteja (CHMP) secināja, ka saskaņā ar ES prasībām ir pierādīta Topotecan Teva un Hycamtin līdzvērtība.
English: When used with cisplatin in cervical cancer, Topotecan Teva is given on days 1, 2 and 3 (with cisplatin given on day 1).
Latvian: Kombinācijā ar cisplatīnu dzemdes kakla vēža terapijai Topotecan Teva ievada infūzijas veidā 1., 2. un 3. dienā (cisplatīnu ievada 1. dienā).
English: Treatment with Topotecan Teva should only be given under the supervision of a doctor experienced in the use of chemotherapy.
Latvian: Ārestēšanu ar Topotecan Teva drīkst veikt tikai tāda ārsta uzraudzībā, kam ir pieredze ķīmijterapijā.
English: Topotecan Teva is a ‘generic medicine'.
Latvian: Topotecan Teva ir „ģenēriskas zāles”.
English: The dose of Topotecan Teva to be used depends on the type of cancer that it is being used to treat and the patient's weight and height.
Latvian: Lietojamā Topotecan Teva deva ir atkarīga no ārstējamā vēža veida un pacientes svara un garuma.
English: The Committee recommended that Topotecan Teva be given marketing authorisation.
Latvian: Komiteja ieteica izsniegt Topotecan Teva reģistrācijas apliecību.
English: Because Topotecan Teva is a generic medicine, the company has provided data from the published literature on topotecan.
Latvian: Tā kā Topotecan Teva ir ģenēriskas zāles, uzņēmums iesniedza publikāciju datus par topotekānu.
English: Topotecan Teva is a concentrate that is made up into a solution for infusion (drip into a vein).
Latvian: Topotecan Teva ir koncentrāts, no kura pagatavo šķīdumu infūzijām (ievadīšanai vēnā pa pilienam).
English: What are the benefit and risk of Topotecan Teva?
Latvian: Kāda ir ieguvumu/riska attiecība, lietojot Topotecan Teva?
English: The full EPAR for Topotecan Teva can be found here.
Latvian: Pilns Topotecan Teva EPAR teksts ir atrodams šeit.
English: Why has Topotecan Teva been approved?
Latvian: Kāpēc Topotecan Teva tika apstiprinātas?
English: The active substance in Topotecan Teva, topotecan, is an anticancer medicine that belongs to the group ‘topoisomerase inhibitors'.
Latvian: Topotecan Teva aktīvā viela topotekāns ir pretvēža zāles, kas pieder topoizomerāzes inhibitoru grupai.
English: Other information about Topotecan Teva:
Latvian: Cita informācija par Topotecan Teva.
English: Because Topotecan Teva is a generic medicine, its benefit and risk are taken as being the same as those of the reference medicine.
Latvian: Tā kā Topotecan Teva ir ģenēriskas zāles, tad šo zāļu ieguvumu/riska attiecību uzskata par līdzvērtīgu atsauces zāļu ieguvumu/riska attiecībai.
English: Topotecan Teva also affects non-cancer cells, which causes side effects.
Latvian: Topotecan Teva ietekmē ne tikai audzēja šūnas, un tas izraisa blakusparādības.
English: What is Topotecan Teva?
Latvian: Kas ir Topotecan Teva?
English: Topotecan Teva is an anticancer medicine.
Latvian: Topotecan Teva ir pretvēža zāles.
English: Topotecan Teva topotecan EPAR summary for the public
Latvian: EPAR kopsavilkums plašākai sabiedrībai
English: No additional studies were needed as Topotecan Teva is a generic medicine that is given by infusion and contains the same active substance as the reference medicine, Hycamtin.
Latvian: Tā kā Topotecan Teva ir ģenēriskas zāles, ko ievada infūzijas veidā un kas satur to pašu aktīvo vielu ko Hycamtin, papildpētījumi nebija nepieciešami.
English: How has Topotecan Teva been studied?
Latvian: Kā noritēja Topotecan Teva izpēte?
English: How is Topotecan Teva used?
Latvian: Kā lieto Topotecan Teva?
English: How does Topotecan Teva work?
Latvian: Kā Topotecan Teva darbojas?
English: Zona Industrial da Abrunheira - Edifício 10 - Sintra Business Park,
Latvian: Edificio 10 Sintra Business Park,
English: 164 94 Kista
Latvian: 16494 Kista Sverige
English: Baxter SPA piazzale dell' industria 2000144-Roma Italy
Latvian: Piazzale dell'Industria 20 00144 Roma Italy
English: 00-380 Warsawa, Poland
Latvian: Kruczkowskiego 8 st., 00-380 Warszawa, Poland
English: Denmark Baxter A/S, Gydevang 43, DK3450 Allerød,
Latvian: Baxter A/S Gydevang 43 3450 Allerød Denmark
English: Baxter Healthcare GmbH, Stella-KleinLöw-Weg 15, A1020 Wien, Austria
Latvian: Baxter Healthcare GmbH Stella-Klein-Löw-Weg 15, A-1020 Wien Austria
English: Belgium Baxter SA Bld R Branquart 80 7860 Lessines Belgium
Latvian: Bd René Branquart 80 B-7860 Lessines Belgium
English: Halandri, 152 33 Greece
Latvian: Diophar SA Kifissias 368 Halandri 15233 Greece
English: 089 Sintra Portugal
Latvian: 2710-089 Sintra
English: Baxter d.o.o., Zelezna cesta 18, Ljubljana, SI-1000, Slovenia
Latvian: Slovēnija Baxter d.o.o., Zelezna cesta 18 ,Ljubljana, SI-1000, Slovenia
English: Annex I
Latvian: N/A
English: Baxter Hungary Kft. Népfürdő u. 22.
Latvian: Baxter Hungary Kft.
English: Baxter B.V., Kobaltweg 49, 3542 CE Utrecht, the Netherlands
Latvian: 3542 CE Utrecht The Netherlands
English: Sverige
Latvian: Zviedrija
English: Edisonstr.
Latvian: Abrunheira,
English: Baxter Healthcare S.A. Moneen Road Castlebar County Mayo IRELAND
Latvian: Baxter Healthcare SA Moneen Road Castlebar, County Mayo Ireland
English: Norfolk IP24 3SE United Kingdom
Latvian: Thetford, Norfolk, IP24 3SE United Kingdom
English: Solution for dialysis peritoneal
Latvian: Solution for peritoneal dialysis
English: 0.0051 % w/v
Latvian: 0,0184% w/v 0,0051% w/v
English: Baxter Healthcare S.A. Moneen Road Castlebar, Co. Mayo Ireland
Latvian: Moneen Road Castlebar, CO. Mayo lreland
English: Norway
Latvian: Norfolk,
English: HEALTHCARE Ltd., Caxton Way, Thetford, Norfolk, 1P24 3SE, Thetford, United Kingdom
Latvian: Thetford, Norfolk, IP24 3SE, United Kingdom
English: Dianeal PD4 med Glucos 13,6 mg/ml
Latvian: Dianeal PD4 Glucose 13,6 mg/ml
English: HEALTHCARE S.A. Moneen Road, Castelbar, County Mayo, Ireland
Latvian: Moneen Road Castlebar, County Mayo Ireland
English: Luxembourg Baxter SA, Bd René Branquart
Latvian: Nīderlande Baxter B.V Kobaltweg 49
English: 5.4 g / l 4.5 g / l 0.184 g / l
Latvian: 0.184 g/l
English: The standard dose of Clopidogrel Acino Pharma is one 75 mg tablet once a day, taken with or without food.
Latvian: Clopidogrel Acino Pharma standarta deva ir viena 75 mg tablete vienreiz dienā kopā ar ēdienu vai bez tā.
English: This means that Clopidogrel Acino Pharma is similar to a ‘reference medicine' already authorised in the European Union (EU) called Plavix.
Latvian: Tas nozīmē, ka Clopidogrel Acino Pharma ir līdzīgas „atsauces zālēm”, kas jau ir reģistrētas Eiropas Savienībā ar nosaukumu Plavix.
English: The European Commission granted a marketing authorisation valid throughout the EU for Clopidogrel Acino Pharma to Acino Pharma GmbH on 21 September 2009.
Latvian: Eiropas Komisija 2009. gada 21. septembrī izsniedza Clopidogrel Acino Pharma reģistrācijas apliecību, kas derīga visā ES, uzņēmumam Acino Pharma GmbH.
English: The Committee for Medicinal Products for Human Use (CHMP) concluded that, in accordance with EU requirements, Clopidogrel Acino Pharma has been shown to have comparable quality and to be bioequivalent to Plavix.
Latvian: Cilvēkiem paredzēto zāļu komiteja (CHMP) secināja, ka saskaņā ar ES prasībām ir pierādīta Clopidogrel Acino Pharma un Plavix kvalitātes līdzvērtība un bioekvivalence.
English: Because Clopidogrel Acino Pharma is a generic medicine and is bioequivalent to the reference medicine, its benefit and risk are taken as being the same as those of the reference medicine.
Latvian: Tā kā Clopidogrel Acino Pharma ir ģenēriskas zāles un ir bioloģiski līdzvērtīgas atsauces zālēm, to ieguvumu/riska attiecību uzskata par līdzvērtīgu atsauces zāļu ieguvumu/riska attiecībai.
English: Clopidogrel Acino Pharma clopidogrel EPAR summary for the public
Latvian: Clopidogrel Acino Pharma klopidogrels EPAR kopsavilkums plašākai sabiedrībai
English: Clopidogrel Acino Pharma can be started between seven days and six months after the stroke;
Latvian: Clopidogrel Acino Pharma terapiju var uzsākt septiņas dienas līdz sešus mēnešus pēc insulta;
English: Clopidogrel Acino Pharma can be started between a few days and 35 days after the attack;
Latvian: Clopidogrel Acino Pharma terapiju var uzsākt dažas dienas pēc lēkmes un līdz 35 dienām pēc tās;
English: Clopidogrel Acino Pharma can be given to the following groups of patients:
Latvian: Clopidogrel Acino Pharma var indicēt šādām pacientu grupām:
English: Clopidogrel Acino Pharma is used in adults to prevent atherothrombotic events (problems caused by blood clots and hardening of the arteries).
Latvian: Clopidogrel Acino Pharma lieto pieauguši pacienti aterotrombotisku traucējumu (problēmu, ko rada trombi un artēriju sacietēšana) profilaksei.
English: Because Clopidogrel Acino Pharma is a generic medicine, studies have been limited to tests to determine that it is bioequivalent to the reference medicine, Plavix.
Latvian: Tā kā Clopidogrel Acino Pharma ir ģenēriskas zāles, pētījumos veica tikai testus, lai noteiktu šo zāļu un Plavix bioekvivalenci.
English: Clopidogrel Acino Pharma is a medicine that contains the active substance clopidogrel.
Latvian: Clopidogrel Acino Pharma ir zāles, kas satur aktīvo vielu klopidogrelu.
English: What are the benefit and risk of Clopidogrel Acino Pharma?
Latvian: Kāda ir ieguvumu un riska attiecība, lietojot Clopidogrel Acino Pharma?
English: The Committee recommended that Clopidogrel Acino Pharma be given marketing authorisation.
Latvian: Komiteja ieteica izsniegt Clopidogrel Acino Pharma reģistrācijas apliecību.
English: The full EPAR for Clopidogrel Acino Pharma can be found here.
Latvian: Pilns Clopidogrel Acino Pharma EPAR teksts ir atrodams šeit.
English: Clopidogrel Acino Pharma is a ‘generic medicine'.
Latvian: Clopidogrel Acino Pharma ir ģenēriskas zāles.
English: Why has Clopidogrel Acino Pharma been approved?
Latvian: Kāpēc Clopidogrel Acino Pharma tika apstiprinātas?
English: Other information about Clopidogrel Acino Pharma:
Latvian: Cita informācija par Clopidogrel Acino Pharma.
English: The active substance in Clopidogrel Acino Pharma, clopidogrel, is an inhibitor of platelet aggregation.
Latvian: Clopidogrel Acino Pharma aktīvā viela klopidogrels ir trombocītu salipšanas inhibitors.
English: What is Clopidogrel Acino Pharma?
Latvian: Kas ir Clopidogrel Acino Pharma?
English: How does Clopidogrel Acino Pharma work?
Latvian: Kā Clopidogrel Acino Pharma darbojas?
English: How is Clopidogrel Acino Pharma used?
Latvian: Kā lieto Clopidogrel Acino Pharma?
English: How has Clopidogrel Acino Pharma been studied?
Latvian: Kā noritēja Clopidogrel Acino Pharma izpēte?
English: EMA/621439/2013 EMEA/V/002700
Latvian: EMA/621439/2013 EMEA/V/C/002700
English: All these signs resolve spontaneously within 24 hours.
Latvian: Visas šīs pazīmes izzūd spontāni 24 stundu laikā.
English: This summary was last updated in July 2019.
Latvian: Šo kopsavilkumu pēdējo reizi atjaunināja 2019.07.
English: Other information about Broadline
Latvian: Cita informācija par Broadline
English: Consequently, it is recommended that recently treated animals do not sleep with owners, especially children.
Latvian: Līdz ar to nesen ārstētiem dzīvniekiem nav ieteicams gulēt kopā ar saimniekiem, īpaši bērniem.
English: The product is to be used only when all three groups of parasites are targeted at the same time.
Latvian: Šīs zāles lieto tikai gadījumos, ja vienlaicīgi tiek apkarotas visas trīs parazītu grupas.
English: Further information on Broadline can be found on the Agency's website: ema.europa.eu/medicines/veterinary/EPAR/broadline.
Latvian: Sīkāka informācija par Broadline ir atrodama aģentūras tīmekļa vietnē: ema.europa.eu/medicines/veterinary/EPAR/broadline.
English: Broadline received a marketing authorisation valid throughout the EU on 4 December 2013.
Latvian: Broadline 2013. gada 4. decembrī tika izsniegta reģistrācijas apliecība, kas derīga visā ES.
English: This means that they kill parasites that live inside the body of animals.
Latvian: Tas nozīmē, ka tie nonāvē parazītus, kas dzīvo dzīvnieku organismā.
English: Fipronil kills adult parasites.
Latvian: Fipronils nonāvē pieaugušos parazītus.
English: Contact with the applicator should be avoided.
Latvian: Jāizvairās no saskares ar aplikatoru.
English: Handling of treated animals should be limited until the application site is dry and children should not play with treated animals during this period.
Latvian: Saskare ar ārstētajiem dzīvniekiem jāierobežo, kamēr uzklāšanas vieta ir nožuvusi, un bērni šajā laikā nedrīkst spēlēties ar ārstētajiem dzīvniekiem.
English: Broadline was 100% effective against the L4 larval stage of heartworm.
Latvian: Broadline bija 100 % iedarbīgas pret sirdstārpa kāpura L4 stadiju.
English: The European Medicine Agency decided that Broadline's benefits are greater than its risks and it can be authorised for use in the EU.
Latvian: Eiropas Zāļu aģentūra nolēma, ka ieguvums, lietojot Broadline, pārsniedz šo zāļu radīto risku un šīs zāles var reģistrēt ES.
English: People applying the medicine should not smoke, eat or drink while doing so and should wash their hands after handling the product.
Latvian: Cilvēki zāļu uzklāšanas laikā nedrīkst smēķēt, ēst vai dzert, un pēc rīkošanās ar zālēm viņiem ir jānomazgā rokas.
English: What benefits of Broadline have been shown in studies?
Latvian: Kādi Broadline ieguvumi atklāti pētījumos?
English: An overview of Broadline and why it is authorised in the EU
Latvian: Broadline pārskats un kāpēc tās ir reģistrētas ES
English: What is Broadline and what is it used for?
Latvian: Kas ir Broadline un kāpēc tās lieto?
English: (S)-methoprene is an insect growth regulator which stops the flea life cycle by killing eggs and blocking the development of juvenile flea stages and causing their death.
Latvian: (S)-metoprēns ir kukaiņu augšanu regulējošs līdzeklis, kas pārtrauc blusu dzīves ciklu, nonāvējot oliņas, bloķējot jaunu blusu attīstības stadijas un izraisot to bojāeju.
English: Broadline can also be used to prevent heartworm disease for one month.
Latvian: Tās var lietot arī sirdstārpu slimības novēršanai vienu mēnesi.
English: It must not be used in rabbits or in cases of hypersensitivity (allergy) to any of the ingredients.
Latvian: Šīs zāles nedrīkst lietot trušiem vai gadījumā, ja ir paaugstināta jutība (alerģija) pret kādu no sastāvdaļām.
English: Why is Broadline authorised in the EU?
Latvian: Kāpēc Broadline tika reģistrētas ES?
English: If the cat licks the application site, temporary excessive salivation may occur.
Latvian: Ja kaķis laiza uzklāšanas vietu, iespējama īslaicīga pastiprināta siekalošanās.
English: The content of one full applicator (appropriate to the cat's weight) is applied directly to the cat's skin after parting the hair, in a single spot on the middle of the neck.
Latvian: Viena pilna aplikatora saturu (atbilstoši kaķa ķermeņa masai) uzklāj tieši uz kaķa ādas, pašķirot spalvu vienā vietā kakla vidusdaļā.
English: If accidental exposure to the eyes occurs, the eyes should be rinsed with water and in case of accidental exposure to the skin, the skin should be washed with soap and water.
Latvian: Ja notikusi nejauša saskare ar acīm, acis jāizskalo ar ūdeni un, ja notikusi nejauša iedarbība uz ādu, āda jānomazgā ar ziepēm un ūdeni.
English: People with known hypersensitivity to any of the ingredients should avoid contact with the product.
Latvian: Cilvēkiem, kuriem ir diagnosticēta paaugstināta jutība pret kādu no sastāvdaļām, jāizvairās no saskares ar šīm zālēm.
English: This means that they kill external parasites that live on the skin or in the fur of animals, such as fleas and ticks.
Latvian: Tas nozīmē, ka tie nonāvē ārējos parazītus, kas dzīvo uz dzīvnieku ādas vai spalvā, piemēram, blusas un ērces.
English: Twenty cats naturally infested with lungworm were treated with Broadline.
Latvian: Divdesmit kaķus, kuri dabīgā ceļā bija invadēti ar plaušu tārpiem, ārstēja ar Broadline.